Omix Ocas 0.4mg

Quick links

Choose a section

Quick links to important sections

Advertisements

Omix Ocas 0.4mg

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Omix Ocas 0.4mg

Property Description
Active Ingredient Tamsulosin Hydrochloride
Form Prolonged-release tablet (Oral Controlled Absorption System - OCAS)
Pharmacological Class Selective alpha1-Adrenoceptor Antagonist (Alpha-Blocker)
Route of Administration Oral
Origin Synthetic

What Type of Drug is Omix Ocas 0.4mg?

Omix Ocas 0.4mg is a synthetic pharmaceutical product containing the active ingredient Tamsulosin Hydrochloride. This medicine is classified as a Selective alpha1-Adrenoceptor Antagonist, falling into the broader category of Alpha-Blockers used for urological purposes. This agent is classified under the Anatomical Therapeutic Chemical (ATC) code G04CA02. Pharmacological studies confirm that Tamsulosin specifically targets the alpha1A and alpha1D adrenoceptors found in the smooth muscle tissue of the prostate and bladder neck, making it a prescription-only medication indicated for adult males.

What Does the OCAS Formulation Mean?

The suffix OCAS refers to the Oral Controlled Absorption System, defining the preparation as a unique modified-release or prolonged-release tablet designed for oral administration. This specialized delivery system is engineered to control the release of the Tamsulosin dose slowly and evenly into the body. The fundamental purpose of this controlled delivery is to maintain consistent therapeutic plasma concentrations over a 24-hour period, which supports a once-daily regimen and continuous symptomatic management.

What is the General Purpose of Tamsulosin in Urology?

The general purpose of the medication is to provide symptomatic relief by inducing the relaxation of the smooth muscles located in the prostate gland and the neck of the bladder. By reducing muscular tension and resistance in this area, the drug improves dynamic obstruction within the urethra. This action allows adult males to experience improved urinary flow, which helps alleviate the discomfort and difficulty associated with lower urinary tract symptoms (LUTS) commonly related to an enlarged prostate.

Advertisements

What side effects are possible with Omix Ocas 0.4mg?

Possible side effects and safety information

The safety profile for Omix Ocas 0.4mg, which contains Tamsulosin Hydrochloride, is defined by adverse reactions classified according to frequency and affected body system, as documented in official regulatory sources.


Frequency-Classified Adverse Reactions

Adverse reactions are organized based on their likelihood, derived from clinical trials and post-marketing surveillance:

Frequency Examples of Adverse Reactions (by Regulatory Classification)
Common Dizziness, Headache, Abnormal Ejaculation
Uncommon Orthostatic Hypotension (dizziness upon standing), Palpitations, Constipation, Diarrhea, Nausea, Vomiting, Rash, Rhinitis, Urticaria
Rare Syncope (fainting), Angioedema (swelling)
Very Rare Priapism (persistent, painful erection), Stevens-Johnson Syndrome

Serious Adverse Reactions and Safety Constraints

The official labeling documents rare but clinically significant events. Serious reactions documented include Priapism, Syncope associated with orthostatic hypotension, and severe skin reactions like Stevens-Johnson Syndrome.

Safety constraints and population-specific considerations are explicitly noted:

  • Surgical Risk: The safety information notes the risk of Intraoperative Floppy Iris Syndrome (IFIS) during cataract or glaucoma surgery, which may increase procedural complexity. This risk can persist even after the medication has been discontinued.
  • Initial Exposure: Effects like Orthostatic Hypotension are specifically documented as being more likely to occur at the start of treatment or following a dose increase.
  • Contraindications: The medicine is contraindicated in individuals with a known history of orthostatic hypotension or severe hepatic impairment, as well as in patients with hypersensitivity to the drug.
Advertisements

Overdose and Emergency Response

The official regulatory documentation on overdose for Omix Ocas (Tamsulosin Hydrochloride) focuses strictly on the potential for acute, severe physiological manifestations stemming from excessive alpha-blockade.

Overdose Classification Official Regulatory Statement
Primary Manifestation Acute Hypotension (a severe drop in blood pressure), Vomiting, and Diarrhoea are the documented clinical presentations associated with overdosage.
Urgent Action Required Seek immediate medical attention for any suspected overdose, particularly if signs of acute hypotension or circulatory collapse are present.

The most serious consequence of overdosage is the development of acute hypotension, which necessitates prompt cardiovascular support. The initial required emergency action is placing the patient in a supine position to aid in restoring blood pressure and heart rate. Further documented medical interventions, if necessary, include the administration of volume expanders and vasopressor agents to manage severe circulatory distress. To reduce systemic absorption of the drug following a large ingestion, procedures such as gastric lavage may be employed, in addition to giving activated charcoal and an osmotic laxative. No specific antidote is known for Tamsulosin overdose, and official information confirms that dialysis is unlikely to be of help. Renal function monitoring is required as part of the mandated general supportive care.

Advertisements

Therapeutic Uses of Omix Ocas 0.4mg

Main Uses of Omix Ocas 0.4mg

Omix Ocas 0.4mg is primarily used to treat the lower urinary tract symptoms associated with an enlarged prostate, a condition medically known as Benign Prostatic Hyperplasia (BPH). While the condition involves the growth of the prostate gland, the medication does not shrink the prostate itself; instead, it focuses on managing the functional symptoms caused by the enlargement.

Benign Prostatic Hyperplasia (BPH)

In individuals with BPH, the enlarged prostate gland can exert pressure on the urethra, the tube through which urine exits the body. This pressure, combined with tension in the smooth muscles of the prostate and the bladder neck, can lead to various obstructive and irritative urinary symptoms.

Benefits and Mechanism of Action

The active ingredient in Omix Ocas 0.4mg belongs to a class of medications called alpha-1 adrenoceptor antagonists. It works by specifically targeting and relaxing the smooth muscles found in the prostate and the neck of the bladder.

Relief of Urinary Symptoms

By reducing the muscle tension in these specific areas, the medication facilitates a more effective flow of urine and helps alleviate common symptoms, which may include:

  • Difficulty starting urination: Reducing the resistance at the bladder neck makes it easier to begin the flow.
  • Weak urinary stream: Improved relaxation allows for a more consistent and stronger flow of urine.
  • Frequent urination: Especially during the night (nocturia), as the bladder can empty more completely.
  • Urgency: A decrease in the sudden, intense need to urinate.
  • Dribbling: Reduction in post-urination leakage.

The OCAS Formulation Advantage

The "Ocas" designation stands for Oral Controlled Absorption System. This specific delivery method is designed to provide a consistent and gradual release of the medication over a 24-hour period. This steady concentration in the blood helps maintain the therapeutic effect throughout the day and night while minimizing the fluctuations that can sometimes lead to side effects.

Advertisements

Eligibility and Restrictions for Use

Official Eligibility for Omix Ocas 0.4mg

Omix Ocas 0.4 mg is indicated exclusively for use in adult males being treated for the signs and symptoms of Benign Prostatic Hyperplasia (BPH). Its use is defined by a strict set of contraindications and conditional use rules established by regulatory authorities.


Populations That Must Not Use the Medicine

Contraindication Basis for Exclusion (Official Labeling)
Hypersensitivity Known allergy to Tamsulosin Hydrochloride or any component of the formulation.
Severe Hepatic Insufficiency Prohibited due to severe liver impairment.
Orthostatic Hypotension History of symptomatic low blood pressure upon standing.

Conditional or Restricted Use

Restriction Status
Severe Renal Impairment Use requires caution as safety and efficacy data are not established.
Pediatric Population Not indicated for use; safety and efficacy have not been established in patients under 18 years.
Scheduled Eye Surgery Initiation of therapy is not recommended for patients awaiting cataract or glaucoma surgery.

Use is generally permitted without dosage adjustment for patients with mild to moderate kidney or liver function impairment. The medicine is not indicated for use in women and is not for pediatric patients.

Advertisements

What should I know about interactions with other medicines?

Omix Ocas 0.4mg, containing Tamsulosin Hydrochloride, has documented interaction patterns primarily governed by the drug's metabolism and its blood pressure-lowering effect. All interactions are based strictly on official regulatory labeling.

Contraindicated Combinations

Co-administration is officially restricted with:

  • Strong Inhibitors of CYP3A4 (e.g., ketoconazole): This combination is contraindicated because the pharmacokinetic interaction causes a significant increase in Tamsulosin exposure.
  • Other Alpha-Adrenergic Blocking Agents: The simultaneous use of other alpha-blockers is contraindicated due to the potential for an additive pharmacodynamic effect, specifically the risk of symptomatic hypotension.

Exposure-Altering and Cautionary Interactions

The medicine is extensively metabolized by CYP3A4 and CYP2D6 enzymes. Consequently, caution is required when combining with:

  • Strong Inhibitors of CYP2D6 (e.g., paroxetine) and Moderate Inhibitors of CYP3A4 or CYP2D6 (e.g., erythromycin, terbinafine). These combinations increase the systemic concentration of Tamsulosin.
  • Cimetidine: This substance decreases Tamsulosin clearance, leading to moderately increased plasma levels.
  • Phosphodiesterase-5 (PDE5) Inhibitors: Caution is advised with agents like sildenafil or tadalafil, as the concomitant use of these vasodilators may lead to additive blood pressure lowering effects and symptomatic hypotension.

Population-Specific Notes

The regulatory label notes caution for individuals identified as CYP2D6 poor metabolizers, particularly at higher doses, as their genetic status leads to a substantial increase in Tamsulosin exposure, comparable to taking a strong CYP2D6 inhibitor.

Advertisements

Mechanism of Action

Selective Alpha-1 Adrenoceptor Blockade

The active ingredient, Tamsulosin, functions as a selective competitive antagonist, targeting the alpha1A and alpha1D adrenoceptor subtypes present on the smooth muscle of the prostate and bladder neck. By binding to these receptors, Tamsulosin interrupts the binding of norepinephrine, thereby blocking the excitatory signals transmitted by the Sympathetic Nervous System (SNS). This action directly modifies the early molecular steps that govern smooth muscle tension.


Modulation of Smooth Muscle Tone and Urethral Resistance

The mechanistic cascade translates this receptor blockade into a functional physiological consequence. By preventing alpha1-receptor activation, the drug inhibits the intracellular signaling that increases calcium and triggers contraction. This induces relaxation of the smooth muscle in the prostate and bladder outlet. The resulting decrease in smooth muscle tension acts upon the dynamic component of obstruction, leading directly to a reduction in urethral resistance and the resulting modulation of flow dynamics. The mechanism is independent of structural prostate tissue mass.

Advertisements

Dosage and Administration Information

Omix Ocas 0.4mg is an Oral Controlled Absorption System (OCAS) prolonged-release tablet and is intended for oral administration only. The instructions for its use detail a standardized, long-term regimen to ensure consistent delivery of the active substance, tamsulosin.

Dosing and Administration Principles

Instruction Detail
Standard Daily Dose 0.4 mg once daily.
Dose Adjustment The dose may be increased to 0.8 mg once daily for patients who have not responded adequately to the 0.4 mg dose after a period of two to four weeks.
Administration Timing The medicine should be taken at the same time each day, approximately one-half hour following the same meal each day.
Tablet Integrity The prolonged-release tablet must be swallowed whole. The tablet must not be crushed, chewed, or opened as this action interferes with the specialized controlled-release mechanism.

Population and Interruption Protocols

No dose adjustment is warranted for use in older adults or in patients with renal impairment or mild to moderate hepatic insufficiency. Tamsulosin is not indicated for use in the pediatric population (under 18 years). If therapy is discontinued or interrupted for several days, the protocol is to re-start the dosing regimen using the initial 0.4 mg once-daily dose.

These instructions define the procedural framework for using the medicine, establishing the standard dose, the once-daily frequency, and the requirement to preserve the tablet’s integrity to maintain the controlled absorption profile.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Omix Ocas 0.4mg

## Evidence for Use in Lower Urinary Tract Symptoms (LUTS) related to BPH

Omix Ocas 0.4mg has been studied in research contexts exploring Lower Urinary Tract Symptoms (LUTS) that are often related to an enlarged prostate, a condition characterized by fluctuating or episodic manifestations known as Benign Prostatic Hyperplasia (BPH). The research base supporting this evaluation includes Randomized Controlled Trials (RCTs). These short-term studies typically compared the drug against a placebo (an inactive treatment) to understand the patterns measured during the study period. Supporting this research are Systematic Reviews and Meta-analyses, which are research efforts used to consolidate the findings from many individual trials.

Research explored the use of Omix Ocas 0.4mg in these research contexts involving fluctuating or unstable symptoms. Findings describe patterns observed in the studies related to outcomes reflecting daily functioning and outcomes related to physical discomfort. Research provides insight into short-term changes, but the findings describe group patterns, not personal outcomes.


## Outcomes Measured in Clinical Trials

To assess symptomatic changes, researchers used standardized rating tools, such as the International Prostate Symptom Score (IPSS), relevant in evidence describing how symptoms are measured. Research describes how symptoms evolved in the observed populations during the trial period.

Functional measures included monitoring the maximum speed of urine flow, known as the maximum urinary flow rate (Qmax). Research examined this measure to record patterns related to functional measures. Studies also monitored other functional metrics, such as the amount of urine remaining in the bladder after passing water (PVR), and the frequency of needing to urinate at night (nocturia).


## Long-Term Studies and Maintenance of Effects

The research exploring outcomes is largely sourced from short-term RCTs (typically 12 weeks to 6 months), but research has also explored the longer-term experience of patients. This long-term data is primarily derived from Open-label Extension Studies. These long-term studies monitored sustained use over defined time intervals. However, because these extension studies are not double-blind, their design is structurally different from the initial double-blind RCTs. The research highlights what is known, but long-term effects are not fully established by the strongest evidence.


## Evidence Gaps and Areas of Uncertainty

While a research base exists for studies observing short-term symptom patterns, the evidence landscape still contains specific gaps and uncertainties. Long-term effects are not fully established by prospective, double-blind trials. Furthermore, comparative evidence is lacking for a demonstrated distinct advantage of this specific formulation against all other available alpha-blockers. The findings were mixed regarding superiority over other similar treatments, and comparative evidence is lacking for a demonstrated distinct advantage of this specific formulation.

Key Studies & References

  1. Tamsulosin Hydrochloride Capsules, 0.4 mg Official Labeling and Clinical Studies (FDA)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Omix Ocas 0.4mg (FAQ)

Q: Can Omix Ocas 0.4mg interact with medications for erectile dysfunction?

A: Official information advises caution when taking Omix Ocas with certain medications, such as Phosphodiesterase-5 (PDE5) inhibitors like sildenafil or tadalafil. The combination may cause additive blood pressure lowering effects, which increases the potential for symptomatic hypotension (a sudden drop in blood pressure that can cause dizziness).

Q: Is there a risk of low blood pressure when first starting Omix Ocas 0.4mg?

A: Regulatory documents state that adverse effects like orthostatic hypotension (dizziness upon standing) are documented. These effects are particularly noted as being more likely to occur when treatment is first started or if a dose is increased.

Q: Can Omix Ocas 0.4mg interact with common pain relievers like ibuprofen?

A: Official regulatory documents do not specifically list common pain relievers, such as nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, as a known interaction that requires dose adjustment or is contraindicated (prohibited). Information regarding known drug interactions is generally focused on blood pressure medications and specific liver enzyme inhibitors.

Q: What is the typical time frame for the maximum benefit of Omix Ocas 0.4mg?

A: The official label notes that a dose increase may be considered if a patient has not responded adequately to the standard daily dose after a period of two to four weeks. The label indicates this is the initial evaluation period for determining the need for a possible dose adjustment.

Q: Is Omix Ocas 0.4mg a type of blood pressure medication?

A: No. Omix Ocas is specifically indicated for treating the signs and symptoms of an enlarged prostate (BPH). The official label explicitly states that it is not indicated for the treatment of high blood pressure (hypertension), even though it belongs to a class of drugs that can affect blood pressure.

Q: Does Omix Ocas 0.4mg help with all symptoms of an enlarged prostate?

A: The medication is indicated for the treatment of the signs and symptoms of Benign Prostatic Hyperplasia (BPH), also known as Lower Urinary Tract Symptoms (LUTS). Its primary mechanism is to relax the smooth muscles in the prostate and bladder neck to improve urinary flow.

Q: Can Omix Ocas 0.4mg cause dizziness or lightheadedness?

A: Yes, regulatory documents list dizziness as a common side effect. Lightheadedness or fainting when changing positions (known as orthostatic hypotension) is also documented as an uncommon adverse reaction.

Q: Do I need to change my diet while taking Omix Ocas 0.4mg?

A: While there are no general dietary restrictions mentioned in the official labeling, the medicine must be taken approximately one-half hour following the same meal each day. The requirement is to take the medicine approximately one-half hour following the same meal each day to maintain the controlled absorption of the drug.

Q: Is it normal for Omix Ocas 0.4mg to affect sexual function?

A: Abnormal ejaculation (retrograde ejaculation), where semen enters the bladder instead of leaving the body, is listed as a common adverse reaction. Priapism (a persistent, painful erection) is also listed as a very rare, serious adverse reaction.

Q: Is it safe to drive after taking Omix Ocas 0.4mg?

A: The official label advises that patients should be aware that adverse reactions such as dizziness and syncope (fainting) may occur. The official label advises that patients should refrain from driving or operating machinery if they experience dizziness or syncope.

Q: Does Omix Ocas 0.4mg affect blood sugar levels?

A: Official regulatory documents do not list an effect on blood sugar levels or complications related to diabetes as a known adverse reaction or precaution for the general population.

Q: How long does the effect of one Omix Ocas 0.4mg tablet last?

A: The OCAS (Oral Controlled Absorption System) formulation is designed as a prolonged-release tablet. Its purpose is to control the release of the active ingredient, tamsulosin, slowly and evenly into the body to maintain consistent therapeutic levels over a 24-hour period, supporting a once-daily dosing regimen.

Q: Does drinking alcohol affect how Omix Ocas 0.4mg works?

A: Official label information does not specify how alcohol chemically changes how the drug works in the body. However, alcohol consumption can increase the risk of low blood pressure or dizziness, and this may heighten the risk of symptomatic low blood pressure associated with the medication.

Q: Can Omix Ocas 0.4mg affect the liver or kidneys?

A: The medicine is strictly contraindicated (prohibited) for use in individuals who have severe hepatic (liver) impairment. The use in severe renal impairment is not recommended because safety and efficacy have not been established.

Q: Does Omix Ocas 0.4mg interact with common cold or flu medicines?

A: Caution is advised regarding the use of Omix Ocas with other agents that can lower blood pressure. It is specifically contraindicated for use with any other alpha-adrenergic blocking agents, some of which may be found in over-the-counter cold and flu preparations.

Q: Is it true that Omix Ocas 0.4mg can affect eye pupils?

A: Official information notes a risk of Intraoperative Floppy Iris Syndrome (IFIS) during cataract or glaucoma surgery. This condition involves the iris (the colored part of the eye) becoming flaccid, and this risk can persist even if the medicine is discontinued before surgery.

Q: What kind of studies support the use of Omix Ocas 0.4mg for its main purpose?

A: The evidence supporting the use of this medicine is based on placebo-controlled, randomized clinical trials. These studies primarily evaluated symptomatic improvement, measured by standardized rating scores, and functional measures such as the maximum urinary flow rate.

Q: What if I experience nasal congestion after taking Omix Ocas 0.4mg?

A: Rhinitis (inflammation of the nasal mucous membrane), which can cause nasal congestion, is listed as an uncommon adverse reaction associated with the medication.

Q: Does this medicine contain sulfa or any common allergens?

A: Tamsulosin, the active substance, is a sulfonamide derivative. The medicine is strictly contraindicated for use in anyone with a known hypersensitivity (allergy) to tamsulosin or any other component listed in the formulation.

Q: Is it safe to combine Omix Ocas 0.4mg with an anticholinergic medication?

A: Regulatory documents do not specifically prohibit the use of anticholinergic medications alongside Omix Ocas. Because of the potential for complex effects on the urinary tract when combining drug classes, concomitant use requires evaluation by a prescriber.

Q: Do I need regular blood tests while on Omix Ocas 0.4mg?

A: Official safety information emphasizes that patients must be evaluated for prostate cancer before starting treatment and periodically thereafter, as this condition may coexist with BPH.

Q: What is the shelf life of Omix Ocas 0.4mg tablets?

A: The shelf life of the medicine is determined by its expiry date, which is indicated on the packaging. The medication should not be used past this date and should be stored according to the official instructions to maintain its stability.

Q: Are there any special precautions for patients with heart conditions taking Omix Ocas 0.4mg?

A: The official label notes the risk of symptomatic hypotension (low blood pressure). Due to this risk, patients with certain cardiovascular conditions may require closer monitoring by a healthcare professional.

Q: Does Omix Ocas 0.4mg help reduce the size of the prostate?

A: The medicine's action is to relax the smooth muscles in the prostate and bladder neck to improve urinary flow and symptoms. Its mechanism is described in official documents as being independent of the structural prostate tissue mass.

Q: Is Omix Ocas 0.4mg available over the counter in some countries?

A: In many regions, including the United States, Omix Ocas (tamsulosin) is classified as a prescription-only medicine. However, regulatory classification can vary globally, so the exact dispensing status should be checked based on the local jurisdiction.

Q: Is it safe to take Omix Ocas 0.4mg if I have been diagnosed with glaucoma?

A: The official label notes the risk of a complication called Intraoperative Floppy Iris Syndrome (IFIS) during cataract or glaucoma surgery. General use in patients with a glaucoma diagnosis without impending surgery is not otherwise restricted.

Q: Can Omix Ocas 0.4mg be taken with statins or cholesterol-lowering drugs?

A: Regulatory documents do not specifically list statins or other common cholesterol-lowering medications as a known interaction requiring dose adjustment or avoidance.

Advertisements

How should Omix Ocas 0.4mg be stored and disposed of?

How to Store and Dispose of Omix Ocas 0.4mg

Omix Ocas 0.4mg (Tamsulosin Hydrochloride) must be stored strictly according to regulatory guidelines to ensure the stability of the Oral Controlled Absorption System (OCAS) formulation.


Official Storage Requirements

Storage Condition Requirement
Temperature Store below 30 C
Protection Keep in the original blister pack to protect from light and moisture
Child Safety Keep out of the sight and reach of children

Disposal Instructions

  • The medication must not be used past the expiry date.
  • Disposal of any unused product or waste material must follow local requirements.
  • Do not discard the medicine via wastewater or standard household waste to help protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Omix Ocas 0.4mg found in:

A-Z Index: